Non-small-cell lung cancer homing peptide-labeled dendrimers selectively transfect lung cancer cells

Gregory Holt, Pirouz Daftarian

Research output: Contribution to journalArticle

Abstract

Aim: Lung cancer gene therapies require reagents to selectively transfect lung tumors after systemic administration. Materials & methods: We created a reagent called NSCLC-NP by attaching a peptide with binding affinity for lung cancer to polyamidoamine dendrimers. The positively charged dendrimers elec-trostatically bind negatively charged nucleic acids, inhibit endogenous nucleases and transfect cells targeted by the attached peptide. Results: In vitro, NSCLC-NP complexed to DNA plasmids bound and transfected three human lung cancer cell lines producing protein expression of the plasmid’s gene. In vivo, systemically administered NSCLC-NP selectively transfected lung cancer cells growing in RAG1KO mice. Conclusion: The capability of NSCLC-NP to selectively transfect lung cancer allows its future use as a vehicle to implement human lung cancer gene therapy strategies.

Original languageEnglish (US)
Pages (from-to)1349-1360
Number of pages12
JournalImmunotherapy
Volume10
Issue number16
DOIs
StatePublished - Jan 1 2018

Fingerprint

Dendrimers
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Peptides
Neoplasm Genes
Genetic Therapy
Plasmids
Nucleic Acids
Gene Expression
Cell Line
Lung
DNA
Neoplasms
Proteins

Keywords

  • Cancer immunology
  • Cancer vaccines
  • DNA plasmid
  • Gene therapy
  • Immunotherapy
  • Molecular immunology
  • Nanoparticles
  • Non-small-cell lung cancer
  • Vaccine vectors

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Non-small-cell lung cancer homing peptide-labeled dendrimers selectively transfect lung cancer cells. / Holt, Gregory; Daftarian, Pirouz.

In: Immunotherapy, Vol. 10, No. 16, 01.01.2018, p. 1349-1360.

Research output: Contribution to journalArticle

@article{036dabb2fb8149ed9a749ab07a89b7c6,
title = "Non-small-cell lung cancer homing peptide-labeled dendrimers selectively transfect lung cancer cells",
abstract = "Aim: Lung cancer gene therapies require reagents to selectively transfect lung tumors after systemic administration. Materials & methods: We created a reagent called NSCLC-NP by attaching a peptide with binding affinity for lung cancer to polyamidoamine dendrimers. The positively charged dendrimers elec-trostatically bind negatively charged nucleic acids, inhibit endogenous nucleases and transfect cells targeted by the attached peptide. Results: In vitro, NSCLC-NP complexed to DNA plasmids bound and transfected three human lung cancer cell lines producing protein expression of the plasmid’s gene. In vivo, systemically administered NSCLC-NP selectively transfected lung cancer cells growing in RAG1KO mice. Conclusion: The capability of NSCLC-NP to selectively transfect lung cancer allows its future use as a vehicle to implement human lung cancer gene therapy strategies.",
keywords = "Cancer immunology, Cancer vaccines, DNA plasmid, Gene therapy, Immunotherapy, Molecular immunology, Nanoparticles, Non-small-cell lung cancer, Vaccine vectors",
author = "Gregory Holt and Pirouz Daftarian",
year = "2018",
month = "1",
day = "1",
doi = "10.2217/imt-2018-0078",
language = "English (US)",
volume = "10",
pages = "1349--1360",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "16",

}

TY - JOUR

T1 - Non-small-cell lung cancer homing peptide-labeled dendrimers selectively transfect lung cancer cells

AU - Holt, Gregory

AU - Daftarian, Pirouz

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Aim: Lung cancer gene therapies require reagents to selectively transfect lung tumors after systemic administration. Materials & methods: We created a reagent called NSCLC-NP by attaching a peptide with binding affinity for lung cancer to polyamidoamine dendrimers. The positively charged dendrimers elec-trostatically bind negatively charged nucleic acids, inhibit endogenous nucleases and transfect cells targeted by the attached peptide. Results: In vitro, NSCLC-NP complexed to DNA plasmids bound and transfected three human lung cancer cell lines producing protein expression of the plasmid’s gene. In vivo, systemically administered NSCLC-NP selectively transfected lung cancer cells growing in RAG1KO mice. Conclusion: The capability of NSCLC-NP to selectively transfect lung cancer allows its future use as a vehicle to implement human lung cancer gene therapy strategies.

AB - Aim: Lung cancer gene therapies require reagents to selectively transfect lung tumors after systemic administration. Materials & methods: We created a reagent called NSCLC-NP by attaching a peptide with binding affinity for lung cancer to polyamidoamine dendrimers. The positively charged dendrimers elec-trostatically bind negatively charged nucleic acids, inhibit endogenous nucleases and transfect cells targeted by the attached peptide. Results: In vitro, NSCLC-NP complexed to DNA plasmids bound and transfected three human lung cancer cell lines producing protein expression of the plasmid’s gene. In vivo, systemically administered NSCLC-NP selectively transfected lung cancer cells growing in RAG1KO mice. Conclusion: The capability of NSCLC-NP to selectively transfect lung cancer allows its future use as a vehicle to implement human lung cancer gene therapy strategies.

KW - Cancer immunology

KW - Cancer vaccines

KW - DNA plasmid

KW - Gene therapy

KW - Immunotherapy

KW - Molecular immunology

KW - Nanoparticles

KW - Non-small-cell lung cancer

KW - Vaccine vectors

UR - http://www.scopus.com/inward/record.url?scp=85057090893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057090893&partnerID=8YFLogxK

U2 - 10.2217/imt-2018-0078

DO - 10.2217/imt-2018-0078

M3 - Article

C2 - 30474481

AN - SCOPUS:85057090893

VL - 10

SP - 1349

EP - 1360

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 16

ER -